Long-term treatment with linezolid in a patient with osteomyelitis undergoing hemodialysis

Núria Berenguer, Olivia Ferrández, Francesc Barbosa, Olatz Urbina, Merçè Espona, Santiago Grau

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


Anemia and/or thrombocytopenia are the most relevant adverse effects of linezolid treatment. We report the case of a patient under hemodialysis who developed osteomyelitis involving the amputation stump of the left limb due to a vancomycin-resistant and teicoplanin-resistant Enterococcus faecium successfully treated with linezolid for 6 months. Close monitorization of the patient probably contributed to maintenance of treatment with linezolid despite hematological alterations observed, which could be attributed to either the underlying patient's clinical condition or antimicrobial treatment. ©2012 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia.
Original languageEnglish
Pages (from-to)226-228
JournalJournal of Chemotherapy
Issue number4
Publication statusPublished - 1 Aug 2012


  • Anemia
  • Hemodialysis
  • Linezolid
  • Thrombocytopenia


Dive into the research topics of 'Long-term treatment with linezolid in a patient with osteomyelitis undergoing hemodialysis'. Together they form a unique fingerprint.

Cite this